Lupus case study Video
The Spectrum of Lupus Nephritis: A Case Based Discussion lupus case studySystemic Lupus Illness: Case Study
This new and updated list of possible lupus-inducing drugs includes a growing range of treatment categories, chemical structures, and pharmacologic actions. Yet it is still unclear what the common denominator is that links them.
Drug-induced lupus DIL is a peculiar adverse drug reaction that appears here be unrelated to any known property of the inducing agent, although cytokine modulating biologics are sttudy possible exception. Nevertheless, the in vivo metabolism of dissimilar drugs to products with a common, reactive property may go some way to explaining how compounds with different pharmacologic and chemical structures could induce similar adverse reactions.
The findings by Arnaud et al. For example, a drug with a relatively high signal does not necessarily translate dtudy a high propensity for causing lupus-like symptoms. It may be a reflection of high drug usage or an awareness of the report contributors for detecting new-onset systemic lupus erythematosus.
Lupus Case Study Examples
Regardless, this research serves to help and inform the medical community to increase the vigilance of previously unreported DIL and perhaps motivate lpus publication lupus case study novel, convincing case reports. Robert L. His comments are adapted from an editorial accompanying the report by Arnaud et al. Ann Rheum Dis.
He reported having no relevant disclosures. DIL was reported as lpus serious adverse event in Arnaud and his colleagues conducted a case-noncase analysis for each drug associated with DIL in order to compare the proportion of specific adverse drug reactions ADRs reported for a single drug with the proportion of the same ADR for all other treatments in VigiBase, which receives reports from more than country members of the WHO Programme for International Drug Monitoring lupus case study contains over 16 million deduplicated ICSRs recorded by pharmacovigilance centers since In line with what the study authors expected, the drugs associated with the highest number of DIL cases were the antitumor necrosis factor agents infliximab, adalimumab, and etanercept, and the drugs associated with the highest disproportional reporting of DIL were procainamide and hydralazine.]
Willingly I accept. In my opinion, it is actual, I will take part in discussion. Together we can come to a right answer. I am assured.
It only reserve, no more